X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-09-27 | MRNA | Afeyan Noubar | Dir | S - Sale | $98.96 | -10,000 | 11,862,969 | 0% | -$989,646 | ||||||
2023-09-20 | MRNA | Afeyan Noubar | Dir | S - Sale | $104.74 | -15,000 | 11,872,969 | 0% | -$1,571,090 | ||||||
2023-09-15 | MRNA | Hoge Stephen | Pres | S - Sale | $112.99 | -15,000 | 1,730,236 | -1% | -$1,694,850 | ||||||
2023-09-13 | MRNA | Afeyan Noubar | Dir | S - Sale | $109.70 | -15,000 | 11,887,969 | 0% | -$1,645,522 | ||||||
D | 2023-09-08 | MRNA | Klinger Shannon Thyme | GC | S - Sale+OE | $107.22 | -557 | 7,215 | -7% | -$59,722 | |||||
2023-09-06 | MRNA | Afeyan Noubar | Dir | S - Sale | $107.61 | -15,000 | 14,868,952 | 0% | -$1,614,094 | ||||||
D | 2023-09-06 | MRNA | Garay Arpa | Chief Commercial Officer | S - Sale+OE | $108.40 | -574 | 3,113 | -16% | -$62,219 | |||||
D | 2023-09-05 | MRNA | Klinger Shannon Thyme | GC | S - Sale+OE | $111.44 | -115 | 6,634 | -2% | -$12,815 | |||||
D | 2023-09-05 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $111.44 | -320 | 1,745,236 | 0% | -$35,660 | |||||
2023-08-30 | MRNA | Afeyan Noubar | Dir | S - Sale | $115.46 | -15,000 | 14,883,952 | 0% | -$1,731,951 | ||||||
D | 2023-08-29 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $115.02 | -1,135 | 1,744,904 | 0% | -$130,542 | |||||
2023-08-23 | MRNA | Afeyan Noubar | Dir | S - Sale | $115.51 | -15,000 | 14,898,952 | 0% | -$1,732,613 | ||||||
2023-08-16 | MRNA | Afeyan Noubar | Dir | S - Sale | $97.56 | -10,000 | 14,913,952 | 0% | -$975,614 | ||||||
2023-08-17 | MRNA | Hoge Stephen | Pres | S - Sale | $100.00 | -15,000 | 1,743,628 | -1% | -$1,500,000 | ||||||
D | 2023-08-10 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $102.53 | -247 | 1,758,628 | 0% | -$25,325 | |||||
2023-08-02 | MRNA | Afeyan Noubar | Dir | S - Sale | $110.99 | -15,000 | 14,923,952 | 0% | -$1,664,876 | ||||||
2023-07-26 | MRNA | Afeyan Noubar | Dir | S - Sale | $120.42 | -15,000 | 14,938,952 | 0% | -$1,806,229 | ||||||
2023-07-19 | MRNA | Afeyan Noubar | Dir | S - Sale | $125.48 | -15,000 | 14,953,952 | 0% | -$1,882,152 | ||||||
2023-07-17 | MRNA | Hoge Stephen | Pres | S - Sale | $120.60 | -15,000 | 1,758,352 | -1% | -$1,809,000 | ||||||
2023-07-12 | MRNA | Afeyan Noubar | Dir | S - Sale | $125.81 | -15,000 | 14,968,952 | 0% | -$1,887,081 | ||||||
2023-07-05 | MRNA | Afeyan Noubar | Dir | S - Sale | $124.73 | -15,000 | 14,983,952 | 0% | -$1,870,933 | ||||||
2023-06-28 | MRNA | Afeyan Noubar | Dir | S - Sale | $121.54 | -15,000 | 14,998,952 | 0% | -$1,823,160 | ||||||
D | 2023-06-28 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $121.63 | -27,155 | 21,027,198 | 0% | -$3,302,907 | |||||
2023-06-21 | MRNA | Afeyan Noubar | Dir | S - Sale | $121.95 | -15,000 | 15,013,952 | 0% | -$1,829,227 | ||||||
DM | 2023-06-21 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $120.70 | -80,000 | 21,027,198 | 0% | -$9,655,714 | |||||
2023-06-14 | MRNA | Afeyan Noubar | Dir | S - Sale | $126.18 | -15,000 | 15,028,952 | 0% | -$1,892,627 | ||||||
DM | 2023-06-14 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $127.27 | -80,000 | 21,027,198 | 0% | -$10,181,874 | |||||
2023-06-15 | MRNA | Hoge Stephen | Pres | S - Sale | $125.93 | -15,000 | 1,773,352 | -1% | -$1,888,950 | ||||||
2023-06-07 | MRNA | Afeyan Noubar | Dir | S - Sale | $125.91 | -15,000 | 15,043,952 | 0% | -$1,888,601 | ||||||
DM | 2023-06-07 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $124.91 | -80,000 | 21,027,198 | 0% | -$9,992,784 | |||||
D | 2023-06-08 | MRNA | Klinger Shannon Thyme | GC | S - Sale+OE | $124.09 | -565 | 6,516 | -8% | -$70,111 | |||||
D | 2023-06-06 | MRNA | Garay Arpa | Chief Commercial Officer | S - Sale+OE | $125.75 | -2,290 | 2,547 | -47% | -$287,972 | |||||
D | 2023-06-02 | MRNA | Klinger Shannon Thyme | GC | S - Sale+OE | $130.32 | -110 | 5,942 | -2% | -$14,336 | |||||
D | 2023-06-02 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $130.32 | -309 | 1,788,352 | 0% | -$40,270 | |||||
2023-05-31 | MRNA | Afeyan Noubar | Dir | S - Sale | $127.36 | -15,000 | 15,058,952 | 0% | -$1,910,322 | ||||||
DM | 2023-05-31 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $127.44 | -80,000 | 21,027,198 | 0% | -$10,195,031 | |||||
D | 2023-05-30 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $124.95 | -1,181 | 1,788,010 | 0% | -$147,569 | |||||
DM | 2023-05-24 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $129.40 | -80,000 | 21,027,198 | 0% | -$10,351,633 | |||||
DM | 2023-05-17 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $124.55 | -80,000 | 21,027,198 | 0% | -$9,963,647 | |||||
DM | 2023-05-10 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $129.43 | -80,000 | 21,027,198 | 0% | -$10,354,519 | |||||
D | 2023-05-10 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $133.37 | -250 | 1,786,781 | 0% | -$33,344 | |||||
DM | 2023-05-03 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $133.50 | -80,000 | 21,027,198 | 0% | -$10,679,623 | |||||
DM | 2023-04-26 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $131.17 | -80,000 | 21,027,198 | 0% | -$10,493,710 | |||||
DM | 2023-04-19 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $142.94 | -80,000 | 21,027,198 | 0% | -$11,434,802 | |||||
DM | 2023-04-12 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $158.72 | -80,000 | 21,027,198 | 0% | -$12,697,675 | |||||
DM | 2023-04-05 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $156.06 | -80,000 | 21,027,198 | 0% | -$12,484,535 | |||||
DM | 2023-03-29 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $148.49 | -80,000 | 21,027,198 | 0% | -$11,879,130 | |||||
DM | 2023-03-22 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $149.72 | -80,000 | 21,027,198 | 0% | -$11,977,488 | |||||
DM | 2023-03-15 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $149.84 | -80,000 | 21,027,198 | 0% | -$11,987,224 | |||||
DM | 2023-03-08 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $140.29 | -80,000 | 21,027,198 | 0% | -$11,223,168 | |||||
D | 2023-03-08 | MRNA | Klinger Shannon Thyme | GC | S - Sale+OE | $141.51 | -561 | 5,820 | -9% | -$79,388 | |||||
2023-03-01 | MRNA | Afeyan Noubar | Dir | S - Sale | $139.00 | -10,000 | 15,073,952 | 0% | -$1,390,000 | ||||||
D | 2023-03-02 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $136.43 | -1,177 | 1,786,509 | 0% | -$160,583 | |||||
D | 2023-03-02 | MRNA | Klinger Shannon Thyme | GC | S - Sale+OE | $136.43 | -459 | 5,243 | -8% | -$62,623 | |||||
DM | 2023-03-01 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $136.34 | -80,000 | 21,027,198 | 0% | -$10,907,157 | |||||
D | 2023-03-01 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $138.03 | -1,072 | 1,785,080 | 0% | -$147,963 | |||||
2023-02-22 | MRNA | Afeyan Noubar | Dir | S - Sale | $160.35 | -10,000 | 15,083,952 | 0% | -$1,603,500 | ||||||
DM | 2023-02-22 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $152.48 | -80,000 | 21,027,198 | 0% | -$12,198,614 | |||||
2023-02-15 | MRNA | Afeyan Noubar | Dir | S - Sale | $173.17 | -10,000 | 15,093,952 | 0% | -$1,731,700 | ||||||
DM | 2023-02-15 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $174.02 | -80,000 | 21,027,198 | 0% | -$13,921,400 | |||||
D | 2023-02-10 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $163.90 | -245 | 1,783,742 | 0% | -$40,156 | |||||
2023-02-08 | MRNA | Afeyan Noubar | Dir | S - Sale | $167.84 | -20,000 | 15,103,952 | 0% | -$3,356,761 | ||||||
DM | 2023-02-08 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $165.79 | -80,000 | 21,027,198 | 0% | -$13,262,877 | |||||
DM | 2023-02-01 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $172.16 | -80,000 | 21,027,198 | 0% | -$13,772,940 | |||||
2023-01-25 | MRNA | Afeyan Noubar | Dir | S - Sale | $194.33 | -10,000 | 15,123,952 | 0% | -$1,943,300 | ||||||
DM | 2023-01-25 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $191.39 | -80,000 | 21,027,198 | 0% | -$15,310,775 | |||||
2023-01-18 | MRNA | Afeyan Noubar | Dir | S - Sale | $200.20 | -10,000 | 15,133,952 | 0% | -$2,002,000 | ||||||
DM | 2023-01-18 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $195.01 | -80,000 | 21,027,198 | 0% | -$15,600,773 | |||||
2023-01-11 | MRNA | Afeyan Noubar | Dir | S - Sale | $188.57 | -10,000 | 15,143,952 | 0% | -$1,885,700 | ||||||
DM | 2023-01-11 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $185.26 | -80,000 | 21,027,198 | 0% | -$14,820,872 | |||||
2023-01-04 | MRNA | Afeyan Noubar | Dir | S - Sale | $182.15 | -10,000 | 15,153,952 | 0% | -$1,821,500 | ||||||
DM | 2023-01-04 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $175.84 | -80,000 | 21,027,198 | 0% | -$14,067,534 | |||||
DM | 2022-12-28 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $178.40 | -90,000 | 21,027,198 | 0% | -$16,055,833 | |||||
D | 2022-12-28 | MRNA | Andres Juan | See remarks | S - Sale+OE | $180.00 | -2,000 | 12,803 | -14% | -$360,000 | |||||
2022-12-21 | MRNA | Afeyan Noubar | Dir | S - Sale | $201.70 | -10,000 | 15,163,952 | 0% | -$2,017,000 | ||||||
DM | 2022-12-21 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $206.60 | -90,000 | 21,037,198 | 0% | -$18,594,122 | |||||
D | 2022-12-21 | MRNA | Andres Juan | See remarks | S - Sale+OE | $201.70 | -2,000 | 12,803 | -14% | -$403,400 | |||||
2022-12-14 | MRNA | Afeyan Noubar | Dir | S - Sale | $195.00 | -10,000 | 15,173,952 | 0% | -$1,950,000 | ||||||
DM | 2022-12-14 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $208.66 | -90,000 | 21,047,198 | 0% | -$18,779,797 | |||||
D | 2022-12-14 | MRNA | Andres Juan | See remarks | S - Sale+OE | $195.00 | -2,000 | 12,803 | -14% | -$390,000 | |||||
2022-12-07 | MRNA | Afeyan Noubar | Dir | S - Sale | $172.16 | -10,000 | 15,183,952 | 0% | -$1,721,600 | ||||||
D | 2022-12-07 | MRNA | Andres Juan | See remarks | S - Sale+OE | $172.16 | -2,000 | 12,803 | -14% | -$344,320 | |||||
DM | 2022-12-07 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $180.32 | -90,000 | 21,057,198 | 0% | -$16,228,583 | |||||
D | 2022-12-08 | MRNA | Klinger Shannon Thyme | GC | S - Sale+OE | $179.15 | -490 | 4,772 | -9% | -$87,783 | |||||
2022-11-30 | MRNA | Afeyan Noubar | Dir | S - Sale | $173.52 | -10,000 | 15,193,952 | 0% | -$1,735,200 | ||||||
DM | 2022-11-30 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $176.28 | -90,000 | 21,067,198 | 0% | -$15,864,993 | |||||
D | 2022-11-30 | MRNA | Andres Juan | See remarks | S - Sale+OE | $173.52 | -2,000 | 12,803 | -14% | -$347,040 | |||||
D | 2022-11-29 | MRNA | Andres Juan | See remarks | S - Sale+OE | $173.80 | -814 | 12,803 | -6% | -$141,475 | |||||
D | 2022-11-29 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $173.80 | -1,085 | 1,783,465 | 0% | -$188,576 | |||||
D | 2022-11-25 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $175.84 | -50,000 | 21,077,198 | 0% | -$8,791,866 | |||||
2022-11-23 | MRNA | Afeyan Noubar | Dir | S - Sale | $178.01 | -10,000 | 15,203,952 | 0% | -$1,780,100 | ||||||
D | 2022-11-23 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $176.20 | -40,000 | 21,087,198 | 0% | -$7,047,892 | |||||
D | 2022-11-23 | MRNA | Andres Juan | See remarks | S - Sale+OE | $178.01 | -2,000 | 11,809 | -14% | -$356,020 | |||||
2022-11-16 | MRNA | Afeyan Noubar | Dir | S - Sale | $184.25 | -10,000 | 15,213,952 | 0% | -$1,842,500 | ||||||
D | 2022-11-16 | MRNA | Andres Juan | See remarks | S - Sale+OE | $184.25 | -2,000 | 11,809 | -14% | -$368,500 | |||||
DM | 2022-11-16 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $183.27 | -90,000 | 21,087,198 | 0% | -$16,494,504 | |||||
DM | 2022-11-09 | MRNA | Bancel Stephane | CEO | S - Sale+OE | $165.51 | -90,000 | 21,097,198 | 0% | -$14,896,262 | |||||
D | 2022-11-10 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $165.59 | -231 | 1,782,140 | 0% | -$38,251 | |||||
DM | 2022-11-09 | MRNA | Andres Juan | See remarks | S - Sale+OE | $162.77 | -2,192 | 11,809 | -16% | -$356,793 | |||||
2022-11-09 | MRNA | Afeyan Noubar | Dir | S - Sale | $162.50 | -10,000 | 15,223,952 | 0% | -$1,625,000 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |